Incidence of Cardiovascular Events in Patients Receiving Hematopoietic Stem Cell Transplant (HSCT) in HCTM – (A Retrospective Cohort Study)

Background: Hematopoietic stem cell transplantation (HSCT) offers curative potential for hematologic malignancies but carries risks of cardiovascular events (CE). Existing data are predominantly from Western populations, with limited evidence from Asian centers.
Objectives: To determine the incidence of short-term (<100 days) and long-term (1-year) cardiovascular events post-HSCT at Hospital Canselor Tuanku Muhriz (HCTM), and to identify associated risk factors, including the usage CARE-BMT score in risk stratification.
Methods: This retrospective cohort study included adult patients who underwent autologous or allogeneic HSCT from 2000 to 2024 at HCTM. Data collected via manual and electronic medical records which included demographics, comorbidities, transplant type, conditioning regimens, and cardiovascular outcomes (heart failure, arrhythmia, myocardial infarction, stroke, cardiac death). Statistical analysis comprises of descriptive and unadjusted univariate tests.
Results: A total of 117 patients were included (63 allogeneic, 54 autologous). The 1-year incidence of cardiovascular events (CE) was 5.1% (6/117), with a higher rate among allogeneic recipients (9.3%) compared to autologous (1.6%). Unadjusted odds ratio (OR) analysis revealed that allogeneic transplant was associated with a higher, albeit nonsignificant, risk of CE (OR 3.84, 95% CI 0.42–34.95). Other factors with elevated but non-significant ORs included obesity (OR 2.91, 95% CI 0.32–26.72), hypertension (OR 2.57, 95% CI 0.28–23.95), and CARE-BMT intermediate/high risk score versus low (OR 7.68, 95% CI 0.86–68.28). Reduced baseline left ventricular ejection fraction (<50%) showed the highest estimated risk (OR 64.7, 95% CI 3.2–1304.8), but with a very wide confidence interval due to limited events. Most events occurred within 100 days post-transplant, and 83% of CE cases had intermediate/high CARE-BMT scores. However, multivariate analysis was limited by the small number of events and wide confidence intervals.
Conclusions: The incidence of cardiovascular events post-HSCT in this Malaysian cohort was comparable to global data, with higher rates in allogeneic recipients and those with intermediate/high CARE-BMT scores. Most events occurred early post-transplant and in patients with traditional or transplant-specific risk factors. CARE-BMT score and baseline cardiac function may help stratify risk. Ongoing monitoring and tailored preventive strategies are necessary for this population. Future larger multi-center, prospective studies are required to confirm these trends and guide targeted cardio-oncology interventions for HSCT recipients in Malaysia.

Incidence of Cardiovascular Events in Patients Receiving Hematopoietic Stem Cell Transplant (HSCT) in HCTM – (A Retrospective Cohort Study)

1. Vasbinder, A., Hoeger, C. W., Catalan, T., Anderson, E., Alblooshi, R., Lord, B., et al. (2023: Cardiovascular events after hematopoietic stem cell transplant: Incidence and risk factors. JACC: CardioOncology. 5:821-832. [Google Scholar] [Crossref]

2. Vasbinder, A., Catalan, T., Anderson, E., Hoeger, C. W., Lord, B., Alblooshi, R., et al. (2024: Cardiovascular risk stratification of patients undergoing hematopoietic stem cell transplantation: The CARE BMT risk score. 13:1. [Google Scholar] [Crossref]

3. Hayek, S. S., Zaha, V. G., Bogle, C., Deswal, A., Langston, A., Rotz, S., Vasbinder, A., Yang, E., & Okwuosa, T. (2024: Cardiovascular management of patients undergoing hematopoietic stem cell transplantation: From pretransplantation to survivorship: A scientific statement from the American Heart Association. Circulation, 149, e1113-e1127. [Google Scholar] [Crossref]

4. Armenian, S. H., Sun, C.-L., Mills, G., Shannon, T., Francisco, L., & Forman, S. J. (2010: Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 16:1138-1144. [Google Scholar] [Crossref]

5. Alblooshi, R., Kanfar, S., Lord, B., Atenafu, E. G., Michelis, F. V., Pasic, I., et al. (2021: Clinical prevalence and outcome of cardiovascular events in the first 100 days post allogeneic hematopoietic stem cell transplant. European Journal of Haematology. 106:32-39. [Google Scholar] [Crossref]

6. Armenian, S. H., Yang, D., Teh, J. B., Mills, G., Chow, E. J., & Sun, C.-L. (2018: Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Advances. 2:1756-1764. [Google Scholar] [Crossref]

7. Miller, L. W. (2002: Cardiovascular toxicities of immunosuppressive agents. American Journal of Transplantation, 2, 807-818. 10.1034/j.1600-6143.2002.20902.x [Google Scholar] [Crossref]

8. Armenian, S. H., Sun, C.-L., Vase, T., Mills, G., Teh, J. B., Francisco, L., et al. (2012: Cardiovascular risk factors in hematopoietic cell transplantation survivors: Role in development of subsequent cardiovascular disease. Blood. 120:4505-4512. [Google Scholar] [Crossref]

9. Chow, E. J., Wong, K., Lee, S. J., Cushing Haugen, K. L., Flowers, M. E. D., Gooley, T. A., et al. (2014: Late cardiovascular complications after hematopoietic cell transplantation. Biology of Blood. 20:794-800. 10.1016/j.bbmt.2014.02.012 [Google Scholar] [Crossref]

10. Murbraech, K., Smeland, K. B., Holte, H., Dörffel, W., Fosså, S. D., & Kiserud, C. E. (2015: Heart failure and asymptomatic left ventricular systolic dysfunction in lymphoma survivors treated with autologous stem cell transplantation: A national cross sectional study. Journal of Clinical Oncology. 33:2683-2691. 10.1200/JCO.2015.60.8125 [Google Scholar] [Crossref]

11. Armenian, S. H., Sun, C.-L., Francisco, L., Mills, G., Teh, J. B., & Forman, S. J. (2008: Late congestive heart failure after hematopoietic cell transplantation. Journal of Clinical Oncology, 26(34), 5537-5543. (DOI. 10.1182/blood-2011-06-358226 [Google Scholar] [Crossref]

12. Cazin, B., Gorin, N. C., Laporte, J., Ifrah, N., Pico, J. L., & Guy, H. (1986: Cardiac complications after bone marrow transplantation. Cancer, 57(10), 2061-2069. (DOI. 10.1002/1097-0142(19860515)57:10<2061::aid-cncr2820571031>3.0.co;2-h [Google Scholar] [Crossref]

13. Buja, L. M., Ferrans, V. J., & Graw, R. G. Jr. (1976: Cardiac pathologic findings in patients treated with bone marrow transplantation. Human Pathology. 7:17-45. 10.1016/s0046-8177(76)80004-4 [Google Scholar] [Crossref]

14. Ghimire, S., Weber, D., Mavin, E., Wang, X. N., Dickinson, A. M., Holler, E., & Socié, G. (2017: Pathophysiology of GvHD and other HSCT related major complications. Frontiers in Immunology. 8:79. [Google Scholar] [Crossref]

15. Tichelli, A., & Gratwohl, A. (2008: Vascular endothelium as 'novel' target of graft versus host disease. Best Practice & Research Clinical Haematology, 21(2), 139-148. (DOI. 10.1016/j.beha.2008.02.002 [Google Scholar] [Crossref]

16. Rovó, A., & Tichelli, A. (2012: Cardiovascular complications in long term survivors after allogeneic hematopoietic stem cell transplantation. Seminars in Hematology. 49:25-34. 10.1053/j.seminhematol.2011.10.001 [Google Scholar] [Crossref]

17. Scott, J. M., Armenian, S., Giralt, S., & Ness, K. K. (2016: Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Critical Reviews in Oncology/Hematology. 98:222-234. 10.1016/j.critrevonc.2015.11.007 [Google Scholar] [Crossref]

18. Sakata Yanagimoto, M., Kanda, Y., Nakagawa, M., Uchida, T., Fukuda, T., & Kodera, Y. (2004: Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplantation. 10:1043-1047. 10.1038/sj.bmt.1704487 [Google Scholar] [Crossref]

19. Nikolousis, E., Nagra, S., Paneesha, S., Pawson, R., Ho, A., & Parapia, L. (2010: Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies. Annals of Hematology. 89:1141-1145. [Google Scholar] [Crossref]

20. Hadjibabaie, M., Tabeefar, H., Alimoghaddam, K., Shams, S., Mousavi, S. A., & Ghavamzadeh, A. (2012: The relationship between body mass index and outcomes in leukemic patients undergoing allogeneic hematopoietic stem cell transplantation. Clinical Transplantation. 26:149-155. 10.1111/j.1399-0012.2011.01445.x [Google Scholar] [Crossref]

• Treasure of 6th Edition of Organon of Medicine- Lm Potency
• Neurobehavioral and Immune-Histochemical Effects of Daucus Carota Ethanolic Leaf Extract in Cadmium-Induced Toxicity of the Hippocampus and Prefrontal Cortex of Adult Wistar Rats
• Unveiling the Antimicrobial Potential of Homoeopathic Sarcode and Bowel Nosode: A Study on Histaminum and Dysenteriae Co against Escherichia Coli And Klebsiella Bacteria
• A Prospective Case Study Examining the Effectiveness of Homoeopathic Medicine in Treating Degenerative Changes in the Lumbar Spine-A Case Report